Baseline Amyloid PET Burden, but Not Longitudinal Change Predicts ARIA-H Risk in the A4 Study (EANM 2026) - Sep 29, 2026 - Abstract #EP-0694; "Materials and We conducted a secondary analysis of data from the A4 study, a randomised, placebo-controlled trial of solanezumab, using multivariable logistic regression... Baseline amyloid burden and APOE ε4 homozygosity are strong risk factors for the development of ARIA-H. Longitudinal change in amyloid burden evaluated between baseline and post therapy PET was non-significant in predicting the risk of ARIA-H. These findings suggest that ARIA-H is driven by pre-existing vascular vulnerability related to established amyloid deposition, rather than dynamic changes in amyloid over time."
Amyloid PET • Alzheimer's Disease • CNS Disorders • APOE
|
|
C. Hill; H. Morgan; S. Michopoulou
|